|
|
Effect of Jianpi Yishen Zhuanggu Decoction on Primary Osteoporosis and Its Influence on Serum IGF-1 MMP-9 and ET-1 |
WEI Haiying, et al |
Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Hubei Enshi 445099, China |
|
|
Abstract Objective: To investigate the therapeutic effect of Jianpi Yishen Zhuanggu Decoction on primary osteoporosis. Methods: 200 patients with primary osteoporosis admitted to our hospital from March 2017 to March 2020 were selected as the research subjects and randomly divided into a control group (n=100) and an observation group (n=100); the control group was administered vitamin D calcium chewable tablets (0.6g / time, 1 time / day) and calcitriol capsules (0.25μg / time, 3 times / day), the observation group was administered Jianpi Yishen Zhuanggu Decoction (1 dose per day) on the basis of the control group. The total effective rate, TCM symptom score, pain visual analogue scale (VAS), lumbar bone mineral density (BMD), biochemical indicators of bone turnover [PINP,β-CTX] and serum levels of insulin-like growth factor-1 (IGF-1), matrix metalloproteinase-9 (MMP-9) and endothelin-1 (ET-1) were compared between the two groups. Adverse reactions were observed. Results: The total effective rate of the observation group was higher than that of the control group (94.00% vs 82.00%) (P<0.05). After 6 months of treatment, the TCM symptom score, VAS score, PINP and β-CTX levels in the observation group were lower than those in the control group (P<0.0 ). The serum IGF-1 in the observation group was higher than that in the control group, and MMP-9 and ET-1 levels were lower than those in the control group (P<0.05). Conclusion: Jianpi Yishen Zhuanggu Decoction has a significant effect on primary osteoporosis, effectively alleviating symptoms, increasing bone density, and improving bone metabolism. The mechanism may be related to the up-regulation of IGF-1 and down-regulation of MMP-9. ET-1 expression is related.
|
|
|
|
|
[1] Richards JB ,Rivadeneira F ,Inouye M ,et al.Bone mineral density,osteoporosis,and osteoporotic fractures:a genome-wide association study[J].Lancet (London,England),2020,371(9623):1505~1512. [2] 顾伏龙,周斌,姜江,等.补肾健脾壮骨方治疗脾肾两虚型原发性骨质疏松症的临床研究[J].中药材,2019,42(1):216~218. [3] 曹成红.血清FGF23,PINP,IGF-1联合检测对绝经期妇女骨质疏松的辅助诊断价值[J].标记免疫分析与临床,2019,26(11):1858~1862. [4] 陈清河,陈闻佳,曾维铨.骨质疏松合并骨关节炎患者血清中Wnt通路调节因子研究[J].中国骨质疏松杂志,2019,25(12):1721~1724,1729. [5] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413~443. [6] 吕琴,赵文晓,王世军,等.黄芪活血功效及现代药理学研究进展[J].中国实验方剂学杂志,2020,26(9):215~224. [7] 国家中医药管理局.中医病证诊断疗效标准[M].南京大学出版社,1994.114~116. [8] 康胜,杨鸫祥,王洪旭,等.基于“养备而动时”理论探讨五禽戏功法防治骨质疏松症研究进展[J].辽宁中医药大学学报,2020,22(4):195~197. [9] 王巧灵.补肾壮骨汤联合针灸治疗骨质疏松效果及对骨代谢及骨转换指标的影响[J].中华中医药学刊,2020,38(9):78~81. [10] 孟彩云,庄扬名.2型糖尿病并发骨质疏松患者胰岛素样生长因子-1,骨碱性磷酸酶及1,25羟维生素D3表达水平及意义[J].临床军医杂志,2019,47(6):628~629. [11] 姚彦冰.骨质疏松与血清IGF-1、ET-1及MMP水平具有相关性[J].基因组学与应用生物学,2018,37(1):123~128. [12] 朱蜀云,马素英.藤黄健骨胶囊联合温针灸治疗原发性骨质疏松症的临床研究[J].中国中医骨伤科杂志,2018,26(1):29~33,38. [13] 杨昌文,侯晓强,张辉军.二仙汤治疗老年类风湿关节炎伴骨质疏松的疗效观察[J].中国中医基础医学杂志,2018,24(10):113~116. |
|
|
|